EU/3/12/1009: Orphan designation for the treatment of Duchenne muscular dystrophy
Table of contents
On 4 July 2012, orphan designation (EU/3/12/1009) was granted by the European Commission to Italfarmaco S.p.A., Italy, for givinostat for the treatment of Duchenne muscular dystrophy.
Treatment of Duchenne muscular dystrophy
|Orphan designation status||
|EU designation number||
|Date of designation||
Via dei Lavoratori, 54
20092 Cinisello Balsamo (MI)
Tel. +39 0264 4325 84
Fax +39 0264 4335 54
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: